Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Industry Concerned Over 26% Sales Tax Prediction For 2023

Potential Impact Of Unprecedented Rebate Rate On Sustainability A Key Concern

Executive Summary

The UK government says it remains committed to the principle of co-creating a positive environment for the development of commercial medicines but there is concern in the life sciences sector over the revelation that companies could be made to pay as much as 26% of their sales in 2023 in rebates to the government.

You may also be interested in...

UK Industry Attacks Government’s ‘Unsustainable’ Repayment Proposals

Questions are being raised about the credibility of the UK’s voluntary and statutory drug pricing schemes because of uncertainty over the payment percentages companies will have to pay in future.

US Industry Hauls Post-Brexit UK Over The Coals

PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.

Older Medicines Rebate Will Test UK’s New Pricing & Access Scheme

As the UK government implements a new rebate system for older medicines as part of the new pricing deal, industry trade bodies and experts suggest that exceptions will have to be made, such as higher prices or lower rebate levels for specific products.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts